|Bid||47.63 x 100|
|Ask||48.30 x 500|
|Day's Range||47.36 - 49.84|
|52 Week Range||16.95 - 63.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2018 - Mar 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.60|
Shares of Exact Sciences (EXAS) are down more than 10% on Wednesday, hurt by news of a potential competitor to its test for colorectal cancer. The American Society for Clinical Oncology (ASCO) announced that a liquid biopsy shows promise at detecting early stage colorectal cancer, and more detail is expected at the association's Gastrointestinal Cancers Symposium this Saturday. In addition, the data is from a single center study in Taiwan, Myers notes, which calls for follow up research, rather than a big selloff in Exact Sciences. Exact Sciences is down 10.2% to $47.57 this afternoon.
NEW YORK, NY / ACCESSWIRE / January 15, 2018 / Concert Pharmaceuticals shares crumbled on Friday after it was revealed that the company's CTP-543 treatment could infringe on Incyte's patent and after CEO ...
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 1.0% convertible senior notes due 2025 (the "Notes"), and upsized the offering from $500 million to $600 million aggregate principal amount, pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90 million aggregate principal amount of Notes. The closing of the offering is expected to occur on January 17, 2018 and is subject to customary closing conditions.
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) today announced an underwritten public offering of $500 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $75 million aggregate principal amount of Notes. The Company intends to use the net proceeds of this offering for general corporate and working capital purposes. The Notes will be convertible into cash, shares of the Company's common stock (plus, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election.
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / It was a day of losses for ACADIA on Monday, closing the day down a little over 6% at $27.11. There was no major news from the company whose stock was trading ...
Jim Cramer lifted the hood on Tesla’s move higher and why he thinks the stock rose despite fewer-than-expected Model 3 deliveries in Q4.
Investors attending the conference want to know if companies are planning more M&A in the wake of tax reform. Pricing practices also could be in focus.
MADISON, Wis., Jan. 7, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company expects to report revenue between $86.9 million and $87.9 million for the fourth quarter ended Dec. 31, 2017, an increase of 148 percent from the same quarter of 2016. The company completed approximately 176,000 Cologuard tests during the fourth quarter of 2017, 115-percent growth from the same period of 2016. Nearly 11,000 health care providers ordered Cologuard for the first time during the fourth quarter ended Dec. 31, 2017. The number of providers who have ordered Cologuard since its launch increased to nearly 102,000 during 2017.
MADISON, Wis., Dec. 20, 2017 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that its executives will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
Investors in the cancer detection company have enjoyed a phenomenal run recently, but where is this business heading in the next half-decade?
NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Phillips ...
Combined lab operations will provide Exact Sciences the capacity to deliver more than 4.5 million Cologuard results per year. Alongside team members, community partners and city officials, Exact Sciences chairman and CEO Kevin Conroy announced the company will build additional laboratory facilities at 650 Forward Drive on the City of Madison's near west side.
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / U.S. markets retreated from their record highs Tuesday on mixed earnings and falling bond yields. The Dow Jones Industrial Average gained 0.04 percent to ...
Fast-growing companies can provide extra performance over time, and that could make adding these top stocks to portfolios smart.